Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.3K
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

9.4K
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
9.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toward a Better Paradigm for Head and Neck Cancer Treatment Applying AI (HNC-TACTIC): Protocol for an International Cohort Study of Electronic Health Records.

JMIR research protocols·2026
Same author

Assessing Financial Toxicity in Cancer: A Global Systematic Review and Meta-Analysis Using an Asset Framework.

Cancer medicine·2026
Same author

Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neck.

Cancer treatment reviews·2026
Same author

Refining the Multivariable Predictive-Prognostic PREDICTR-OPC Model for Survival in Surgical Escalation for Oropharyngeal Squamous Cell Carcinoma.

The Laryngoscope·2026
Same author

Regional HNSCC metabolomics reveals widespread changes to one-carbon metabolism and S-adenosylmethionine metabolism across tumour core, tumour edge and adjacent non-tumour tissues.

British journal of cancer·2026
Same author

HPV-Associated Oropharyngeal Squamous Cell Carcinoma - Key Updates to the AJCC/UICC TNM9 Staging System.

Annals of surgical oncology·2026

Related Experiment Video

Updated: Oct 28, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.5K

WEE1 Inhibitor: Clinical Development.

Anthony Kong1,2, Hisham Mehanna3

  • 1Institute of Head and Neck Studies (InHANSE), University of Birmingham, Birmingham, UK. anthony.kong@kcl.ac.uk.

Current Oncology Reports
|July 16, 2021
PubMed
Summary

WEE1 inhibitors show promise in enhancing cancer treatment sensitivity, but clinical trials reveal challenges with toxicity and modest benefits. Future research focuses on novel combinations to improve efficacy and safety.

Keywords:
AZD1775AdavosertibBiomarkerClinical trialsTP53 mutationWEE1 inhibitor

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.2K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.4K

Related Experiment Videos

Last Updated: Oct 28, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.5K
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.2K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.4K

Area of Science:

  • Oncology
  • Cancer Therapeutics
  • Clinical Trials

Background:

  • WEE1 inhibitor demonstrates potential in sensitizing cancer cells to chemotherapy and radiotherapy, particularly in p53-mutated or deficient cancers.
  • Preclinical models suggest WEE1 inhibition can enhance treatment sensitivity.

Purpose of the Study:

  • To review the clinical development of WEE1 inhibitors in combination therapies.
  • To evaluate WEE1 inhibitor combinations with chemotherapy, radiotherapy, and novel agents.

Main Methods:

  • Review of clinical trial data for WEE1 inhibitor combinations.
  • Analysis of safety and efficacy of WEE1 inhibitor in various treatment settings.

Main Results:

  • Clinical trials indicate WEE1 inhibitors can be safely combined with chemotherapy and radiotherapy.
  • Higher rates of grade 3 toxicities observed when WEE1 inhibitors are added to standard treatments.
  • TP53 mutation status has not proven to be a reliable predictive biomarker for WEE1 inhibitor efficacy.
  • Modest clinical benefits observed even in TP53 biomarker-driven studies.

Conclusions:

  • WEE1 inhibitor development faces challenges due to toxicity and modest efficacy in current combinations.
  • Ongoing trials exploring WEE1 inhibitors with novel agents (ATR inhibitors, PARP inhibitors, anti-PDL1 immunotherapy) may redefine its future role.
  • Future success depends on identifying combinations with superior anti-tumor efficacy and favorable safety profiles.